MCID: OVR105
MIFTS: 37

Ovarian Serous Carcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Carcinoma

MalaCards integrated aliases for Ovarian Serous Carcinoma:

Name: Ovarian Serous Carcinoma 12 15 17
Ovarian Serous Adenocarcinoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050933
UMLS 70 C1335177

Summaries for Ovarian Serous Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in the lining of the ovary and produces a serum-like fluid.

MalaCards based summary : Ovarian Serous Carcinoma, also known as ovarian serous adenocarcinoma, is related to endometrial cancer and melanoma. An important gene associated with Ovarian Serous Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Gemcitabine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, bone and breast.

Related Diseases for Ovarian Serous Carcinoma

Diseases related to Ovarian Serous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 endometrial cancer 29.1 MIR27A MIR200C MIR200B MIR200A MIR199A1 MIR145
2 melanoma 28.8 MIRLET7B MIR27A MIR23B MIR200C MIR200B MIR200A
3 endometriosis 28.3 MIR99A MIR20A MIR200B MIR200A MIR199A1 MIR145
4 ovarian cancer 27.6 MIR99A MIR29A MIR27A MIR214 MIR21 MIR200C
5 pancreatic cancer 27.1 MIR99A MIR23B MIR23A MIR214 MIR21 MIR20A
6 colorectal cancer 25.2 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
7 primary peritoneal carcinoma 11.2
8 ovarian epithelial cancer 10.4
9 benign mesothelioma 10.3
10 peritoneal mesothelioma 10.2
11 cystadenoma 10.2
12 renal hypertension 10.2 MIR200B MIR200A MIR141
13 mesothelioma, malignant 10.2
14 adenocarcinoma 10.2
15 ovarian serous cystadenocarcinoma 10.2
16 endometrial serous adenocarcinoma 10.2
17 aortic disease 10.1 MIR21 MIR199A1 MIR145
18 retinal vascular disease 10.1 MIR21 MIR20A MIR199A1
19 renal fibrosis 10.1 MIR214 MIR21 MIR200B MIR199A1
20 cervix carcinoma 10.1 MIR214 MIR200A MIR199A1 MIR141
21 papillary adenocarcinoma 10.1
22 papillary carcinoma 10.1
23 serous cystadenocarcinoma 10.1
24 carcinosarcoma 10.1
25 endometrioid ovary carcinoma 10.1
26 malignant peritoneal mesothelioma 10.1
27 esophagus adenocarcinoma 10.1 MIR21 MIR199A1 MIR145 MIR143
28 bile duct adenocarcinoma 10.1 MIR21 MIR199A1 MIR145 MIR125A
29 central nervous system cancer 10.1 MIR21 MIR199A1 MIR145 MIR125A
30 infratentorial cancer 10.1 MIR20A MIR199A1 MIR100
31 gallbladder disease 10.0 MIR199A1 MIR145 MIR143
32 bone cancer 10.0 MIR21 MIR199A1 MIR145 MIR125A
33 lymphoma, hodgkin, classic 10.0 MIR21 MIR20A MIR200A
34 mature b-cell neoplasm 10.0 MIR23B MIR199A1 MIR125A
35 cerebral arterial disease 10.0 MIR199A1 MIR145 MIR143 MIR125A
36 leiomyoma, uterine 10.0 MIR27A MIR23B MIR21
37 lung cancer susceptibility 3 10.0 MIR21 MIR200C MIR200B MIR200A MIR145
38 integumentary system disease 10.0 MIR21 MIR199A1 MIR125A
39 endocrine organ benign neoplasm 10.0 MIR93 MIR21 MIR199A1
40 pleural disease 10.0 MIRLET7B MIR199A1 MIR125A
41 autoimmune disease of musculoskeletal system 9.9 MIR27A MIR21 MIR199A1 MIR125A
42 alopecia, androgenetic, 1 9.9
43 pelvic organ prolapse 9.9
44 thyroid cancer, nonmedullary, 1 9.9
45 tuberous sclerosis 1 9.9
46 wilms tumor 1 9.9
47 testicular germ cell tumor 9.9
48 brittle bone disorder 9.9
49 tumor predisposition syndrome 9.9
50 cutaneous telangiectasia and cancer syndrome, familial 9.9

Graphical network of the top 20 diseases related to Ovarian Serous Carcinoma:



Diseases related to Ovarian Serous Carcinoma

Symptoms & Phenotypes for Ovarian Serous Carcinoma

Drugs & Therapeutics for Ovarian Serous Carcinoma

Drugs for Ovarian Serous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 1 95058-81-4 60750
2
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
3
Olaparib Approved Phase 1 763113-22-0 23725625
4 Immunosuppressive Agents Phase 1
5 Antiviral Agents Phase 1
6 Anti-Infective Agents Phase 1
7 Antimetabolites Phase 1
8 Immunologic Factors Phase 1
9 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
10 BIRC5 protein, human

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer Recruiting NCT02627443 Phase 1 Berzosertib;Carboplatin;Gemcitabine Hydrochloride
2 A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer Recruiting NCT04633239 Phase 1 Abemaciclib;Olaparib
3 Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients Completed NCT02016833
4 Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas Recruiting NCT03606486
5 Data Collection for Patients With Low Grade Ovarian Carcinoma Recruiting NCT00488878

Search NIH Clinical Center for Ovarian Serous Carcinoma

Genetic Tests for Ovarian Serous Carcinoma

Anatomical Context for Ovarian Serous Carcinoma

MalaCards organs/tissues related to Ovarian Serous Carcinoma:

40
Ovary, Bone, Breast, Cervix, Thyroid, Pancreas, Skin

Publications for Ovarian Serous Carcinoma

Articles related to Ovarian Serous Carcinoma:

(show top 50) (show all 461)
# Title Authors PMID Year
1
MicroRNA expression profiles in serous ovarian carcinoma. 47
18451233 2008
2
Genetic risk score for ovarian cancer based on chromosomal-scale length variation. 61
33750420 2021
3
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance. 61
33654182 2021
4
The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor. 61
32168063 2021
5
Expression and molecular profiles of the AlkB family in ovarian serous carcinoma. 61
33744868 2021
6
Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. 61
32801341 2021
7
PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma. 61
33552280 2021
8
Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report. 61
33593410 2021
9
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target. 61
33635867 2021
10
Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective. 61
33493131 2021
11
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma. 61
33452985 2021
12
Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma. 61
33049689 2021
13
The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma. 61
33288561 2020
14
High-grade ovarian serous carcinoma presenting as androgenetic alopecia. 61
33471889 2020
15
MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells. 61
33313239 2020
16
Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. 61
33203969 2020
17
Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report. 61
33252399 2020
18
Primary retroperitoneal serous adenocarcinoma: A case report of rare malignancy with literature review. 61
33402586 2020
19
A Rare Case of Pseudo-Meigs' Syndrome With Ovarian Metastasis Presenting as Meigs' Syndrome. 61
33214950 2020
20
Transcriptome sequencing identifies genes associated with invasion of ovarian cancer. 61
32878513 2020
21
Hemophagocytic syndrome with histiocytic glomerulopathy associated with ovarian serous carcinoma. 61
33456183 2020
22
Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types. 61
32203152 2020
23
Bleeding and bowel obstruction in giant ovarian serous carcinoma - a video vignette. 61
31967392 2020
24
Hysterectomy and Oophorectomy in Reproductive Age: A Cross-Sectional Study from a Tertiary Care Hospital. 61
32617218 2020
25
Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma. 61
32366394 2020
26
Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. 61
31165997 2020
27
Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. 61
31876585 2020
28
Differential expression of immune related genes in high-grade ovarian serous carcinoma. 61
31918995 2020
29
Synchronous Cervical Adenocarcinoma and Ovarian Serous Adenocarcinoma-A Case Report and Literature Review. 61
32235322 2020
30
A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling. 61
32169072 2020
31
Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding. 61
32098383 2020
32
Surprise Lymph Node Histology in a Patient with Ovarian Serous Carcinoma. 61
32095299 2020
33
Compartment Syndrome of the Hand after Laparoscopic Gynecologic Surgery. 61
30936029 2020
34
The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma. 61
33030731 2020
35
Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma. 61
30383611 2020
36
Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment. 61
32257787 2020
37
Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. 61
32020965 2020
38
Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database. 61
31888704 2019
39
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. 61
31771601 2019
40
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. 61
31766991 2019
41
An Unlikely Route: Metastatic Ovarian Malignancy within the Duodenum. 61
31768358 2019
42
Difficult Diagnosis of Peritoneal Serous Papillary Carcinoma in a 63-year-old Woman: A Case Report. 61
31448396 2019
43
A Comprehensive Review of Ovarian Serous Carcinoma. 61
31368906 2019
44
A Shallow Convolutional Learning Network for Classification of Cancers Based on Copy Number Variations. 61
31569801 2019
45
miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis. 61
30834603 2019
46
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 61
31337420 2019
47
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 61
31208449 2019
48
Metastatic Carcinoma of Endometrium from Primary Ovarian Serous Carcinoma Mimicking a Primary Uterine Tumour. 61
31133160 2019
49
Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma. 61
30915911 2019
50
Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature. 61
30950130 2019

Variations for Ovarian Serous Carcinoma

Copy number variations for Ovarian Serous Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 109396 17 25800000 31800000 Deletion NF1 Ovarian serous carcinoma

Expression for Ovarian Serous Carcinoma

Search GEO for disease gene expression data for Ovarian Serous Carcinoma.

Pathways for Ovarian Serous Carcinoma

Pathways related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.09 MIRLET7B MIR99A MIR29A MIR27A MIR23B MIR23A
2 11.13 MIR93 MIR27A MIR23B MIR23A MIR145 MIR100
3 11.09 MIR200C MIR200B MIR200A MIR141
4 10.37 MIR199A1 MIR145

GO Terms for Ovarian Serous Carcinoma

Cellular components related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
2 extracellular exosome GO:0070062 9.81 MIRLET7B MIR29A MIR27A MIR23A MIR21 MIR145
3 extracellular vesicle GO:1903561 9.4 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B

Biological processes related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.05 MIR93 MIR29A MIR23A MIR214 MIR21
2 positive regulation of apoptotic process GO:0043065 9.99 MIR29A MIR23A MIR21 MIR200B
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 MIRLET7B MIR27A MIR23B MIR23A MIR21
4 positive regulation of protein kinase B signaling GO:0051897 9.93 MIR29A MIR21 MIR199A1 MIR143
5 negative regulation of cell migration GO:0030336 9.92 MIR93 MIR29A MIR214 MIR21 MIR145
6 negative regulation of gene expression GO:0010629 9.91 MIR93 MIR29A MIR27A MIR23B MIR214 MIR21
7 negative regulation of inflammatory response GO:0050728 9.87 MIR20A MIR145 MIR141
8 negative regulation of angiogenesis GO:0016525 9.87 MIR29A MIR214 MIR21 MIR200B MIR145 MIR143
9 positive regulation of osteoblast differentiation GO:0045669 9.85 MIR27A MIR21 MIR20A MIR200C
10 positive regulation of angiogenesis GO:0045766 9.85 MIRLET7B MIR29A MIR21 MIR20A MIR199A1 MIR143
11 negative regulation of protein kinase B signaling GO:0051898 9.84 MIR29A MIR20A MIR200C MIR145
12 positive regulation of endothelial cell migration GO:0010595 9.82 MIR29A MIR21 MIR199A1
13 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.8 MIR20A MIR200C MIR199A1
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR27A MIR214 MIR21 MIR20A
15 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.78 MIR21 MIR20A MIR199A1 MIR145
16 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.77 MIR21 MIR20A MIR143
17 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.76 MIR27A MIR23B MIR23A MIR10B
18 positive regulation of vascular endothelial cell proliferation GO:1905564 9.75 MIR29A MIR27A MIR21
19 cell growth involved in cardiac muscle cell development GO:0061049 9.73 MIR23B MIR23A MIR199A1
20 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.73 MIR27A MIR23B MIR23A MIR20A
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.71 MIR93 MIR20A MIR199A1 MIR125A
22 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.69 MIR214 MIR21
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.69 MIR214 MIR20A MIR199A1
24 negative regulation of cardiac muscle cell proliferation GO:0060044 9.68 MIR200B MIR199A1
25 positive regulation of endothelial cell differentiation GO:0045603 9.68 MIR21 MIR200C
26 negative regulation of cardiac muscle hypertrophy GO:0010614 9.68 MIR21 MIR145
27 regulation of smooth muscle contraction GO:0006940 9.68 MIR145 MIR143
28 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR27A MIR199A1
29 positive regulation of connective tissue replacement GO:1905205 9.67 MIR214 MIR199A1
30 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.67 MIR99A MIR125A
31 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.66 MIR21 MIR125A
32 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.66 MIR141 MIR125A
33 angiotensin-activated signaling pathway GO:0038166 9.65 MIR145 MIR143
34 negative regulation of STAT cascade GO:1904893 9.64 MIR99A MIR125A
35 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 MIR27A MIR21
36 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.63 MIRLET7B MIR27A MIR23B MIR23A MIR21 MIR10B
37 aorta smooth muscle tissue morphogenesis GO:0060414 9.62 MIR145 MIR143
38 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.62 MIR20A MIR143
39 gene silencing by miRNA GO:0035195 9.62 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
40 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.61 MIRLET7B MIR21
41 regulation of phenotypic switching GO:1900239 9.61 MIR145 MIR143
42 miRNA mediated inhibition of translation GO:0035278 9.61 MIR29A MIR27A MIR21 MIR20A MIR200C MIR200B
43 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.59 MIR145 MIR143
44 negative regulation of interleukin-16 production GO:0032699 9.58 MIR145 MIR125A

Molecular functions related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.8 MIR93 MIR29A MIR27A MIR23B MIR23A MIR21
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.62 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
3 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR145 MIR125A

Sources for Ovarian Serous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....